Home / Health / New Diabetes Pill Outshines Ozempic Oral
New Diabetes Pill Outshines Ozempic Oral
13 Jul
Summary
- New drug orforglipron shows superior blood sugar reduction.
- Orforglipron led to greater average weight loss.
- The drug, Foundayo, gained FDA approval in April.
A new daily medication, orforglipron, is demonstrating superior effectiveness in managing Type 2 diabetes, according to recent clinical trial findings. Developed by Eli Lilly and marketed as Foundayo, the drug secured FDA approval in April.
A year-long Phase 3 trial involving nearly 1,700 adults with Type 2 diabetes across six countries revealed that orforglipron significantly reduced HbA1c levels more than oral semaglutide. Participants also achieved more substantial weight loss, averaging approximately 15 pounds compared to roughly 10 pounds with the oral medication.
Further studies are exploring orforglipron's potential benefits for individuals with obesity who do not have diabetes. The drug's performance suggests a new advancement in diabetes and weight management therapies.
